Howard Colman

Huntsman Cancer Institute, University of Utah

Disclosure: NO DISCLOSURE DATA

Presentation(s):

• QOLP-09 - Impact of glioblastoma (GBM) patients’ clinical and treatment characteristics on caregiver burden and quality of life (QoL)

  Friday, November 22
  2:45 PM – 2:50 PM

• COMP-10 - The mutational profile of glioblastoma-derived cell-free DNA in plasma represents a distinct subset of the somatic mutations present in glioblastoma solid tumor DNA

  Friday, November 22
  7:30 PM – 9:30 PM

• ACTR-39 - Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory (R/R) glioblastoma (GBM); phase 1b/2 study update

  Saturday, November 23
  5:00 PM – 7:00 PM

• ACTR-52 - Phase 1 study of FT-2102, an inhibitor of mutant IDH1, in patients with relapsed/refractory IDH1 mutant gliomas: preliminary safety and clinical activity

  Saturday, November 23
  5:20 PM – 5:24 PM

• Clinical and Clinical Trial Impact of cIMPACT Recommendations

  Sunday, November 24
  8:00 AM – 8:30 AM

• ATIM-33 - Interim Results of a Phase II Multi-center Study of Oncolytic Adenovirus DNX-2401 with Pembrolizumab for Recurrent Glioblastoma; CAPTIVE Study (KEYNOTE-192)

  Sunday, November 24
  8:55 AM – 9:05 AM